Agilent Technologies (NYSE:A) Price Target Lowered to $135.00 at Sanford C. Bernstein

Agilent Technologies (NYSE:A) had its price objective lowered by equities researchers at Sanford C. Bernstein from $140.00 to $135.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “market perform” rating on the medical research company’s stock. Sanford C. Bernstein’s target price suggests a potential downside of 2.25% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Wells Fargo & Company began coverage on Agilent Technologies in a report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 target price for the company. Bank of America raised their price target on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. UBS Group upped their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. Citigroup lifted their price objective on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $143.40.

Agilent Technologies Stock Performance

NYSE:A opened at $138.11 on Tuesday. The company has a market capitalization of $39.68 billion, a P/E ratio of 31.25, a P/E/G ratio of 5.91 and a beta of 1.07. The business has a fifty day simple moving average of $137.72 and a two-hundred day simple moving average of $137.43. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies has a 1 year low of $124.10 and a 1 year high of $155.35.

Insider Activity

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This represents a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds have recently made changes to their positions in the business. Tidal Investments LLC lifted its position in shares of Agilent Technologies by 8.2% in the 3rd quarter. Tidal Investments LLC now owns 14,752 shares of the medical research company’s stock worth $2,187,000 after purchasing an additional 1,113 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Agilent Technologies in the third quarter worth about $535,000. World Investment Advisors LLC boosted its position in Agilent Technologies by 4.7% during the 3rd quarter. World Investment Advisors LLC now owns 4,466 shares of the medical research company’s stock valued at $663,000 after acquiring an additional 201 shares in the last quarter. SkyView Investment Advisors LLC grew its holdings in shares of Agilent Technologies by 5.2% during the 3rd quarter. SkyView Investment Advisors LLC now owns 3,615 shares of the medical research company’s stock worth $537,000 after acquiring an additional 178 shares during the period. Finally, Rehmann Capital Advisory Group bought a new position in shares of Agilent Technologies in the 3rd quarter worth approximately $236,000.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.